ライフサイエンスコーパス: relapsing

1 w to accurately determine which patients are relapsing.

2 sue, with almost half of patients ultimately relapsing.

3 eliably predicted current smoking as well as relapsing 20 years later.

4 neuromyelitis optica spectrum disorders and relapsing acute disseminated encephalomyelitis, and char

5 ASCT) in patients with multiple myeloma (MM) relapsing after a prior autologous stem-cell transplanta

6 ivolumab as a single agent in 20 HL patients relapsing after allo-HCT.

7 al states of microglia/macrophages in acute, relapsing and progressive multiple sclerosis.

8 uantitative susceptibility mapping from both relapsing and progressive patients demonstrate a higher

9 isorder characterized by clonal diversity, a relapsing and remitting course, and in its aggressive fo

10 ne point in time and, in most people, runs a relapsing and remitting course.

11 s, and nervous system, and take a chronic or relapsing and remitting disease course.

12 nflammatory bowel disease (IBD) is a chronic relapsing and remitting inflammatory disease of the gast

13 Crohn's disease is a relapsing and remitting inflammatory disorder with a var

14 oids on fatigue has not been investigated in relapsing and remitting multiple sclerosis (RRMS).

15 is a frequent skin disease characterized by relapsing appearance of pruritic hives.

16 orders of the inflammasome may contribute to relapsing attacks; and 4) therapies that target the infl

17 utoantibody-associated vasculitis, a chronic relapsing autoimmune inflammatory disease associated wit

18 body has been identified as a biomarker of a relapsing autoimmune meningoencephalomyelitis that is im

19 is optica spectrum disorder (NMOSD), a rare, relapsing, autoimmune, inflammatory disease of the CNS t

20 reatment of an immunosuppressed patient with relapsing babesiosis.

21 harmacological strategies for persistent and relapsing bacteremia and found that a persister killer,

22 But, fourth, when relapsing bacteremia was considered, the growth rate of

23 he bladder, this treatment failed to prevent relapsing bacteriuria.

24 negative emotional state leading to chronic relapsing behavior.

25 rinary tract and prevents the development of relapsing bouts of bacteriuria.

26 ytic colitis (LC)), traditionally considered relapsing but non-progressive diseases, is poorly define

27 rat model, healthy adults, and children with relapsing CD.

28 (FFT) in 5 patients with symptomatic chronic-relapsing CDI at the Department of Internal Medicine I a

29 adult-dominant unselected cohort with mainly relapsing central nervous system (CNS) inflammatory dise

30 Considering its chronic relapsing character, accurate and timely diagnosis of an

31 ive compared to 14.1% (95% CI = 4.7-38.3) of relapsing children (log-rank p < 0.001), with no differe

32 disease become MOG-Ab negative earlier than relapsing children, but this is not true in adults.

33 rosis according to 2010 McDonald criteria, a relapsing clinical course, brain MRI lesions consistent

34 sive to antimicrobial therapy and exhibits a relapsing clinical course; an effective vaccine is there

35 We identified a high prevalence of relapsing CMV viremia in IPF-LTRs compared with non-IPF-

36 dult-predominant unselected cohort of mainly relapsing CNS inflammatory diseases, we confirmed that N

37 Bipolar disorder is a chronic relapsing condition in which mood episodes are intersper

38 Inflammatory bowel disease is a chronic, relapsing condition with two subtypes, Crohn's disease (

39 Opioid use disorder (OUD) is a chronic, relapsing condition, often associated with legal, interp

40 disease and ulcerative colitis, are chronic relapsing conditions that affect a growing number of chi

41 Patients with a relapsing course (median number of relapses = 1, range:

42 hereas the majority of German patients had a relapsing course and more frequent myelitis, findings co

43 g children but also occurs in adults, with a relapsing course in approximately 50% of patients.

44 D4(+)IL-17A(+)CD44(+)) drive the chronic and relapsing course of dry eye disease.

45 A relapsing course suggested an increased risk for visual

46 g and withdrawal, often leading to a chronic relapsing course.

47 of all those diagnosed developing chronic or relapsing disease by adolescence.

48 ered the risk of visual loss, independent of relapsing disease course (OR = 0.79; 95% CI, 0.66-0.94,

49 iated clinically with either a monophasic or relapsing disease course.

50 Relapsing disease is common among immunocompromised and

51 h a positive predictive value for clinically relapsing disease of only 20%.

52 s were significantly higher in 176 pwMS with relapsing disease than 92 with progressive disease (2124

53 entify parasite variants that associate with relapsing disease, including amino acid substitutions in

54 mutation can become the predominant clone in relapsing disease.

55 Opioid addiction is a chronic, relapsing disorder associated with persistent changes in

56 Drug addiction is a chronic relapsing disorder of compulsive drug use.

57 STATEMENT Alcohol use disorder is a chronic relapsing disorder that is associated with compulsive al

58 Opioid use disorder (OUD) is a chronic relapsing disorder that, whilst initially driven by acti

59 Addiction is a chronic relapsing disorder, and during recovery many people expe

60 limus is approved for tamoxifen-resistant or relapsing estrogen receptor-positive breast cancer, thes

61 spinal cord of mice subjected to chronic or relapsing experimental autoimmune encephalomyelitis.

62 The patient was also complicated by a relapsing facial nodule on the right cheek.

63 However, overactive, relapsing fear behavior in the absence of danger is a ha

64 Tick-borne relapsing fever (RF) borreliosis is a neglected disease

65 The global public health impact of relapsing fever (RF) spirochetosis is significant, since

66 texposure prophylaxis regimen for tick-borne relapsing fever (TBRF) consists of 5 days' doxycycline.

67 Tick-borne relapsing fever (TBRF) is a neglected zoonotic bacterial

68 Tick-borne relapsing fever (TBRF) is caused by several Borrelia spp

69 Relapsing fever group species are found worldwide, excep

70 Relapsing fever is a common clinical phenotype.

71 Relapsing fever pattern was reported in 52% of patients,

72 Relapsing fever pattern was reported in 52%, weight loss

73 disease, B. miyamotoi is closely related to relapsing fever spirochetes, such as Borrelia hermsi i S

74 should be considered a hard-tick-transmitted relapsing fever, and thus, the main mode of confirming a

75 the Western Front reported on a soldier with relapsing fever, headache, dizziness, lumbago, and shin

76 strong contrast to the diagnosis of typical relapsing fever, microscopy of blood smears is not sensi

77 ase, syphilis, leptospirosis, and tick-borne relapsing fever.

78 a miyamotoi has recently been shown to cause relapsing fever.

79 This review provides an overview of early-relapsing FL and our approach to patient management base

80 and Drug Administration for the treatment of relapsing forms of multiple sclerosis (MS).

81 decades have revolutionized the treatment of relapsing forms of multiple sclerosis.

82 Prostate cancer relapsing from antiandrogen therapies can exhibit varian

83 g therapy was associated with risk, patients relapsing from very good partial response (VGPR) or bett

84 st line may be those patients who are either relapsing from VGPR or better (dFLC at diagnosis was >5

85 and in a model derived from an AFP-negative relapsing HB.

86 Thirty-three patients with a unilateral and relapsing herpes simplex keratitis (HSK group) that was

87 iescent phase of the disease, unilateral and relapsing HSK significantly impairs the QoL of patients

88 nce in the number of hospitalisations due to relapsing IBD during follow-up.

89 nt, akin to humans with alcohol use disorder relapsing in the face of adversity.

90 d by lesions in progressive subtypes than in relapsing in voxelwise analysis (P < 0.001), which was f

91 We performed whole-exome sequencing on 10 relapsing individuals and 11 controls from 5 nuclear fam

92 en, responsible for a variety of chronic and relapsing infections such as osteomyelitis, endocarditis

93 Crohn's disease (CD) is a chronic relapsing inflammatory bowel disease (IBD) that may be m

94 er channel on astrocytes are associated with relapsing inflammatory neuromyelitis optica spectrum dis

95 Hidradenitis suppurativa (HS) is a chronic, relapsing, inflammatory skin disease.

96 Inflammatory bowel disease causes chronic, relapsing intestinal inflammation that can lead to the d

97 The risk of relapsing into depression after stopping antidepressants

98 The most striking findings were relapsing, large, contrast-enhancing focal lesions in th

99 The phenomenon of relapsing malaria has been recognised for centuries.

100 ovale curtisi and wallikeri are perceived as relapsing malarial parasites.

101 d network activities that are altered in non-relapsing mice, which enabled us to find that activating

102 tive cohort, more than half of patients with relapsing MS accumulated significant new disability by t

103 generation and more rapid remyelination make relapsing MS more resilient than the progressive subtype

104 Long-term worsening is common in relapsing MS patients, is largely independent of relapse

105 ulatory medications that effectively control relapsing MS.

106 selective B-cell depletion in patients with relapsing multiple sclerosis (MS) and primary progressiv

107 ng monoclonal antibody, effectively inhibits relapsing multiple sclerosis (MS) but is associated with

108 Participants (aged 18-58 years) with relapsing multiple sclerosis (relapsing-remitting multip

109 rate (DMF) is indicated for the treatment of relapsing multiple sclerosis and may exert therapeutic e

110 ble-dummy phase 3 trial in participants with relapsing multiple sclerosis at 147 medical centres and

111 Clinical trials in patients with relapsing multiple sclerosis have focused on pairwise co

112 ent options for disease-modifying therapy in relapsing multiple sclerosis have substantially increase

113 and Drug Administration for the treatment of relapsing multiple sclerosis including active secondary

114 tive stress and axonal damage in chronic and relapsing multiple sclerosis models.

115 ed, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: plac

116 randomly assigned 821 and 835 patients with relapsing multiple sclerosis to receive intravenous ocre

117 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofa

118 In participants with relapsing multiple sclerosis treated for at least 12 mon

119 Patients with relapsing multiple sclerosis were recruited from 55 acad

120 Patients with relapsing multiple sclerosis who received 75 mg of evobr

121 , crossover trial (ReBUILD) in patients with relapsing multiple sclerosis with chronic demyelinating

122 enrolled participants aged 18-55 years with relapsing multiple sclerosis, baseline expanded disabili

123 Among patients with relapsing multiple sclerosis, ocrelizumab was associated

124 RADIANCE phase 2 study in participants with relapsing multiple sclerosis, ozanimod was associated wi

125 24-month phase 3 study in participants with relapsing multiple sclerosis, ozanimod was well tolerate

126 re novel modes of action in the treatment of relapsing multiple sclerosis, which are exhibited by min

127 imod as an oral therapy for individuals with relapsing multiple sclerosis.

128 and efficacy of opicinumab in patients with relapsing multiple sclerosis.

129 ersus interferon beta-1a in individuals with relapsing multiple sclerosis.

130 with fingolimod were tested in patients with relapsing multiple sclerosis.

131 improve the quality of life of patients with relapsing multiple sclerosis.

132 ourable safety profile, in participants with relapsing multiple sclerosis.

133 effective oral therapy for individuals with relapsing multiple sclerosis.

134 ivity in two phase 3 trials of patients with relapsing multiple sclerosis.

135 receptor modulator ozanimod in patients with relapsing multiple sclerosis.

136 gression in a phase 3 trial of patients with relapsing multiple sclerosis.

137 ular interferon beta-1a in participants with relapsing multiple sclerosis.

138 phase 3 trial is underway, in patients with relapsing multiple sclerosis.

139 ility compared with placebo in patients with relapsing multiple sclerosis.

140 ndrocyte DNA was identified in patients with relapsing multiple sclerosis; neuronal/glial DNA was ide

141 ded, especially given the disease's chronic, relapsing nature.

142 ude a separate category of complex inherited relapsing neuropathy syndromes, some of which may mimic

143 adult patients (aged >=18 years) with highly relapsing NMOSD diagnosed according to 2015 Internationa

144 mab and azathioprine in patients with highly relapsing NMOSD.

145 bcortical gray matter fraction in women with relapsing-onset MS (standard beta = -1.20 x 10-1; P = 1.

146 significant difference was observed between relapsing-onset MS and primary progressive MS.

147 rial, we randomly assigned participants with relapsing or refractory eosinophilic granulomatosis with

148 subsets at onset and 4 weeks associated with relapsing or remitting HCMV viremia.

149 In this region of frequent relapsing P. vivax, failure rates after supervised high-

150 ver schizonts and dormant hypnozoites of the relapsing parasite Plasmodium cynomolgi.

151 All relapsing patients had choroidal tumors and 15 presented

152 toward advanced phase CML occurred, and all relapsing patients regained MMR and MR4.5 after restarti

153 Median survival of relapsing patients was 59 months.

154 that these lesions can be identified in the relapsing patients.

155 i-PD-1 therapy with or without ipilimumab in relapsing patients.

156 Tackling relapsing Plasmodium vivax and zoonotic Plasmodium knowl

157 nical criteria for an inflammatory syndrome (relapsing polychondritis, Sweet's syndrome, polyarteriti

158 itis, Crohn disease, multiple sclerosis, and relapsing polychondritis.

159 parallel-group trial recruited patients with relapsing/refractory EGPA receiving stable OGCs (prednis

160 he CSF of multiple sclerosis patients with a relapsing remitting (n = 15) or a progressive (secondary

161 ical trial of AHSCT for patients with active relapsing remitting (RRMS) and secondary progressive MS

162 secondary progressive disease and 14 with a relapsing remitting disease course) underwent T1- and T2

163 Because atopic dermatitis (AD) is a relapsing remitting disease, assessing long-term control

164 d in MS by comparing the fecal microbiota in relapsing remitting MS (RRMS) (n = 31) patients to that

165 ith secondary progressive MS [SPMS], 27 with relapsing remitting MS [RRMS]) and 30 healthy volunteers

166 FTY720 is a treatment for relapsing remitting multiple sclerosis (MS).

167 rom the cerebrospinal fluid of patients with relapsing remitting multiple sclerosis (RRMS) have highe

168 Thirty-nine patients with relapsing remitting multiple sclerosis, at high risk of

169 were enrolled in this study, 24 patients had relapsing remitting multiple sclerosis, six had progress

170 the CSF of progressive patients compared to relapsing remitting multiple sclerosis.

171 ation reflected behaviour in the subgroup of relapsing remitting patients (rho = 0.74, P = 0.008).

172 ctions of white matter lesion enlargement in relapsing remitting patients and is associated with grea

173 ohort, and by 31% (MLM) and 14% (Markov) for relapsing remitting patients.

174 tients (22 clinically isolated syndrome, 198 relapsing remitting, 39 secondary progressive, 31 primar

175 and efficacy of amiselimod in patients with relapsing- remitting multiple sclerosis.

176 sed DNA methylation in the CD4(+) T cells of relapsing-remitting (RR) MS patients compared to healthy

177 copy, we analysed the lipoprotein profile of relapsing-remitting (RR) MS patients, progressive MS pat

178 PMS) patients, but not in a third cohorts of relapsing-remitting (RRMS) patients.

179 Individuals suffering from relapsing-remitting and secondary progressive MS had sig

180 cervical spinal cord of patients with early relapsing-remitting and secondary progressive multiple s

181 ealthy donors and MS patients in the initial relapsing-remitting and subsequent secondary-progressive

182 nearest the subpial surfaces for those with relapsing-remitting and the central canal CSF surface in

183 Behcet disease is a chronic, relapsing-remitting autoinflammatory syndrome with a str

184 em traditionally characterized by an initial relapsing-remitting clinical course and focal inflammato

185 Over 9 mo, these mice exhibited a relapsing-remitting course of hind-limb clasping with th

186 s (MS) is a neuroinflammatory disease with a relapsing-remitting disease course at early stages, dist

187 e determined that pEVs induced a spontaneous relapsing-remitting disease phenotype in MOG(35-55)-immu

188 ssion (C-PRO group) and chronic disease with relapsing-remitting episodes (C-RELAP group).

189 causal role of IL-11 in the exacerbation of relapsing-remitting experimental autoimmune encephalomye

190 d progressive, as well as PLP138-151-induced relapsing-remitting experimental autoimmune encephalomye

191 d on the 2010 McDonald criteria (34 with the relapsing-remitting form, 2 with clinically isolated syn

192 , whereas the classifier that differentiates relapsing-remitting from progressive MS achieved a valid

193 males with progressive disease compared with relapsing-remitting males (RRMS) and female MS subjects,

194 disease relapses and remissions in the SJL/J-relapsing-remitting model of EAE, and could comparably a

195 Using a relapsing-remitting model of EAE, here we demonstrate th

196 ants with secondary progressive MS than with relapsing-remitting MS (3.6 lesions/year +/- 4.2 vs 1.1

197 Participants were 31 patients with Relapsing-Remitting MS (mean age = 44.323 +/- 13.149; me

198 ts with a diagnosis of either PPMS (n = 16), relapsing-remitting MS (n = 20), or benign MS (n = 20) a

199 Patients with active relapsing-remitting MS (n=20) and healthy controls (n=8)

200 can serve as a biomarker of regeneration in relapsing-remitting MS (RRMS) and whether disease-modify

201 Patients with relapsing-remitting MS (RRMS) or clinically isolated syn

202 d from clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS) to SPMS.

203 were reconstructed from diffusion data in 58 relapsing-remitting MS (RRMS), 28 primary progressive MS

204 ulatory (EDSS scores <=3.5), all of whom had relapsing-remitting MS (RRMS), 3 (4%) had RRMS and EDSS

205 nal fluid (CSF) and blood from subjects with relapsing-remitting MS (RRMS; n = 12), other neurologic

206 nd April 2019, 120 patients with MS (58 with relapsing-remitting MS [RRMS] and 62 with progressive MS

207 atic carriers of HTLV-1 (AC), 47 HAM/TSP, 74 relapsing-remitting MS [RRMS], 17 secondary progressive

208 (52 clinically isolated syndrome [CIS], 196 relapsing-remitting MS [RRMS], 34 progressive MS [PMS]),

209 terials and Methods Twenty participants with relapsing-remitting MS and 13 with secondary progressive

210 Twenty-five patients with relapsing-remitting MS and 20 healthy control subjects u

211 Fifty-seven consecutive patients with relapsing-remitting MS and 30 healthy, age-matched contr

212 One hundred patients with relapsing-remitting MS and 50 healthy controls.

213 nce images were acquired from 133 women with relapsing-remitting MS and analyzed using voxel-based mo

214 the lateral funiculi and gray matter (GM) in relapsing-remitting MS and GM atrophy in patients with p

215 written informed consent, six patients with relapsing-remitting MS and six healthy control subjects

216 ters in 21 countries examining patients with relapsing-remitting MS commencing DMTs (or clinical moni

217 onal cohort study included 312 patients with relapsing-remitting MS in 2 independent cohorts (72 pati

218 Disease course was classified as CIS, relapsing-remitting MS or secondary progressive MS (SPMS

219 In the present study, 15 relapsing-remitting MS patients receiving 1,000 mg of ri

220 Ten relapsing-remitting MS patients were studied using the T

221 Relapsing-remitting MS patients who developed PML under

222 second independent cohort of untreated early relapsing-remitting MS patients.

223 creased in peripheral blood of patients with relapsing-remitting MS with a high disease score.

224 d July 7, 2016, a total of 110 patients with relapsing-remitting MS, at least 2 relapses while receiv

225 Among patients with relapsing-remitting MS, initial treatment with fingolimo

226 ing tool for identifying novel therapies for relapsing-remitting MS, it has proven to be less success

227 In this preliminary study of patients with relapsing-remitting MS, nonmyeloablative HSCT, compared

228 the disease activity, among 99 patients with relapsing-remitting MS, who underwent blinded clinical a

229 e therapeutic target for patients with early relapsing-remitting MS.

230 he approval of IFN-beta for the treatment of relapsing-remitting MS.

231 d with worsening of disease in patients with relapsing-remitting MS.

232 atients who satisfy traditional criteria for relapsing-remitting MS.

233 174 relapsing-remitting MS/CIS patients were included in thi

234 atients with clinically isolated syndrome or relapsing-remitting multiple sclerosis (Expanded Disabil

235 e cerebrospinal fluid of patients with early relapsing-remitting multiple sclerosis (MS) and in activ

236 n the brains and spinal cords of people with relapsing-remitting multiple sclerosis (MS) and progress

237 des of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a

238 iety of human autoimmune diseases, including relapsing-remitting multiple sclerosis (MS), in which in

239 to slow or prevent progressive disability in relapsing-remitting multiple sclerosis (MS).

240 ical and MRI activity in adult patients with relapsing-remitting multiple sclerosis (MS).

241 ger-type lesion' in an independent cohort of relapsing-remitting multiple sclerosis (RRMS) and AQP4-a

242 cting fingolimod (FTY) treatment response in relapsing-remitting multiple sclerosis (RRMS) are lackin

243 tokine polarization profile in patients with relapsing-remitting multiple sclerosis (RRMS) by high-di

244 e total circulating exosome transcriptome in relapsing-remitting multiple sclerosis (RRMS) patients a

245 e previously showed that memory B cells from relapsing-remitting multiple sclerosis (RRMS) patients e

246 Many JC virus antibody-positive relapsing-remitting multiple sclerosis (RRMS) patients w

247 (CSF) samples collected over 12 months from relapsing-remitting multiple sclerosis (RRMS) patients.

248 The transition from relapsing-remitting multiple sclerosis (RRMS) to seconda

249 s normal aging, or can be distinguished from relapsing-remitting multiple sclerosis (RRMS).

250 a control cohort of neurologic autoimmunity (relapsing-remitting multiple sclerosis [MS] n = 110, HD

251 During the clinical relapse of both, relapsing-remitting multiple sclerosis and neuromyelitis

252 58 years) with relapsing multiple sclerosis (relapsing-remitting multiple sclerosis and secondary pro

253 d data from propensity-matched patients with relapsing-remitting multiple sclerosis from the MSBase a

254 at have regulatory approval for treatment of relapsing-remitting multiple sclerosis have little or no

255 Analysis of pEVs from relapsing-remitting multiple sclerosis patients also ide

256 nd 4-6 and 18-26 mo Tecfidera-treated stable relapsing-remitting multiple sclerosis patients using mu

257 m safety and effectiveness of natalizumab in relapsing-remitting multiple sclerosis patients.

258 312 on MRI Lesion Given Once Daily) Study in relapsing-remitting multiple sclerosis provides evidence

259 Subjects with relapsing-remitting multiple sclerosis showed a greater

260 The mechanism underlying the progression of relapsing-remitting multiple sclerosis to secondary prog

261 olimod, and interferon beta in patients with relapsing-remitting multiple sclerosis treated for up to

262 ggestive of CNS demyelination and typical of relapsing-remitting multiple sclerosis, a complete neuro

263 than interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy

264 lusion criteria were a diagnosis of definite relapsing-remitting multiple sclerosis, exposure to one

265 A) is widely prescribed for the treatment of relapsing-remitting multiple sclerosis, however, the mec

266 ns is the underlying pathological process in relapsing-remitting multiple sclerosis, the gradual accu

267 tified adult patients (aged >=18 years) with relapsing-remitting multiple sclerosis, with at least 6

268 Fingolimod is an effective treatment for relapsing-remitting multiple sclerosis.

269 the central nervous system of patients with relapsing-remitting multiple sclerosis.

270 the first mAb approved for the treatment of relapsing-remitting multiple sclerosis.

271 milar effects on annualised relapse rates in relapsing-remitting multiple sclerosis.

272 rug Administration approved for treatment of relapsing-remitting multiple sclerosis.

273 negative prognostic factor in patients with relapsing-remitting multiple sclerosis.

274 3.6 +/- 2.7% and 2.9 +/- 2.4%), compared to relapsing-remitting patients (1.6 +/- 2.1%, both P < 0.0

275 quency was higher in progressive compared to relapsing-remitting patients, with significant bilateral

276 reduced in secondary progressive relative to relapsing-remitting patients.

277 ity and related clinical relapses during the relapsing-remitting phase of the disease.

278 ent disease-modifying agents for its initial relapsing-remitting phase, these therapies show limited

279 he article presents a case of a patient with relapsing-remitting severe BBE.

280 lindromic rheumatism often being viewed as a relapsing-remitting variant of RA.

281 We prospectively recruited 20 relapsing-remitting, 15 secondary progressive multiple s

282 PHOMS were present in 16% of patients with relapsing-remitting, 16% of patients with progressive, a

283 : 119 (72%) had multiple sclerosis [94 (57%) relapsing-remitting, 25 (15%) secondary progressive], 45

284 lthy controls and 122 patients comprising 58 relapsing-remitting, 28 primary progressive and 36 secon

285 ts (31 clinically isolated syndrome, and 416 relapsing-remitting, 84 secondary progressive, and 73 pr

286 XA1 to influence T cell effector function in relapsing/remitting MS (RRMS), an autoimmune disease sus

287 and lymphocyte counts mirrored the remitting/relapsing SARS-CoV-2 infection.

288 Atopic dermatitis (AD) is a chronic relapsing skin disease prevalent in 1% to 3% of adults i

289 re met: (1) acquired, chronic progressive or relapsing symmetrical or asymmetrical polyneuropathy wit

290 Herpes simplex virus (HSV) causes acute and relapsing symptoms characterized by ulcerative lesions.

291 In a phase 3 study of patients with relapsing symptoms of IBS-D, repeat rifaximin treatment

292 ctice Advice 11: Patients with persistent or relapsing symptoms, without other obvious explanations f

293 women, and its outcome is characterized by a relapsing tendency.

294 ng of treatment, still show many individuals relapsing to illicit opioid use.

295 PD-1/PD-L1 pathway to provide resistance to relapsing uveitis and shows a reduced capacity of uveiti

296 rolled trial, adults with newly diagnosed or relapsing vasculitis received placebo plus prednisone st

297 abolites most altered in rats with active or relapsing vasculitis were trimethylamine N-oxide (TMAO),

298 sk of CMV complications (P < 0.01) including relapsing-viremia episodes, end-organ disease, and CMV r

299 Comparison of outcomes in patients with a relapsing vs nonrelapsing disease also were analyzed.

300 ses, but with ultimate recovery (22.5%); and relapsing without recovery (14.7%).